ArticleSchizophrenia bulletin2017
Pitch and Duration Mismatch Negativity and Premorbid Intellect in the First Hospitalized Schizophrenia Spectrum.
Article in Schizophrenia bulletin, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- EEG-Based Measures in At-Risk Mental State and Early Stages of Schizophrenia: A Systematic Review.Frontiers in psychiatry · 2021Pooled it
- Meta-analysis of mismatch negativity to simple versus complex deviants in schizophrenia.Schizophrenia research · 2018Pooled it
- Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Trial
- Mismatch Negativity and P3a in Unaffected Siblings of Individuals with Autism Spectrum Disorder and the Exploration on the Neurocognitive Implications.Journal of autism and developmental disorders · 2026Article
- Development of Biomarkers Potentially Sensitive to Early Psychosis Using Mismatch Negativity (MMN) to Complex Pattern Deviations.Clinical EEG and neuroscience · 2025Article
- Identify Potential Causal Relationships Between Cortical Thickness, Mismatch Negativity, Neurocognition, and Psychosocial Functioning in Drug-Naïve First-Episode Psychosis Patients.Schizophrenia bulletin · 2024Article
- Is source-resolved magnetoencephalographic mismatch negativity a viable biomarker for early psychosis?The European journal of neuroscience · 2024Article
- Mismatch Negativity (MMN) as a Pharmacodynamic/Response Biomarker for NMDA Receptor and Excitatory/Inhibitory Imbalance-Targeted Treatments in Schizophrenia.Advances in neurobiology · 2024Review
- Assessing Trial-to-Trial Variability in Auditory ERPs in Autism and Schizophrenia.Journal of autism and developmental disorders · 2023Article
- Why mismatch negativity continues to hold potential in probing altered brain function in schizophrenia.PCN reports : psychiatry and clinical neurosciences · 2023Review
- Event-related potential (ERP) markers of 22q11.2 deletion syndrome and associated psychosis.Journal of neurodevelopmental disorders · 2023Review
- Diminished Auditory Cortex Dynamic Range and its Clinical Correlates in First Episode Psychosis.Schizophrenia bulletin · 2023Article
- Computational Modeling of Oddball Sequence Processing Exposes Common and Differential Auditory Network Changes in First-Episode Schizophrenia-Spectrum Disorders and Schizophrenia.Schizophrenia bulletin · 2023Article
- Automatic auditory processing features in distinct subtypes of patients at clinical high risk for psychosis: Forecasting remission with mismatch negativity.Human brain mapping · 2022Article
- Atypical prediction error learning is associated with prodromal symptoms in individuals at clinical high risk for psychosis.Schizophrenia (Heidelberg, Germany) · 2022Article
- Auditory perceptual discomfort and low-hearing tolerance in the first episode psychosis.Psicologia, reflexao e critica : revista semestral do Departamento de Psicologia da UFRGS · 2022Article
- Decreased mismatch negativity and elevated frontal-lateral connectivity in first-episode psychosis.Journal of psychiatric research · 2021Article
- Hierarchical Pathways from Sensory Processing to Cognitive, Clinical, and Functional Impairments in Schizophrenia.Schizophrenia bulletin · 2021Article
- Sources of the frontocentral mismatch negativity and P3a responses in schizophrenia patients and healthy comparison subjects.International journal of psychophysiology : official journal of the International Organization of Psychophysiology · 2021Article
- Longitudinal relationships between mismatch negativity, cognitive performance, and real-world functioning in early psychosis.Schizophrenia research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
Mismatch negativity (MMN) is a robustly abnormal brainwave in chronically ill schizophrenia that has generated interest as a disease presence biomarker. Reports of MMN reduction in first-episode schizophrenia have been equivocal, raising uncertainty about its reduction at first psychotic break. Here we tested 29 schizophrenia-spectrum participants under 1 year from their first hospitalization for psychosis and 40 age-, gender-, parental socioeconomic status-, and Wechsler Adult Intelligence Scales III Information-matched healthy controls on both pitch and duration MMN. Participants performed a visual checkerboard tracking task while standard (1kHz, 50ms, 80%), pitch-deviant (1.2kHz, 50ms, 10%) and duration-deviant (1kHz, 100ms, 10%) tones were presented over headphones (75 dB) and EEG was recorded. Independent component analysis was used to remove eye movements and visual stimulus processing activity. Groups did not differ in pitch MMN or duration MMN amplitudes. Smaller pitch and duration MMN amplitudes were associated with lower estimates of premorbid intellect in all participants and independently with greater positive symptoms in first hospitalized schizophrenia. Overall MMN reduction was not present in these relatively high functioning individuals at the first episode of schizophrenia, and therefore is not a good disease presence biomarker for this sample. Future research is warranted to determine the degree of MMN reduction at the first episode of psychosis across a greater range of cognitive impairment, the utility of MMN as an indicator of risk or diagnosis, and its role for understanding pathophysiological mechanisms in emerging psychosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.